|Awarded On||February 16, 2022|
|Title||IRE-based Rational Combination for Effective PDAC Immunotherapy|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Chun Li|
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer. The current project offers a promising solution that simultaneously kills tumor cells and change the tumor's microenvironment in favor of boosting our own body's defense system, i.e., the hosts' immune system.
Our group has found that a clinically used tumor ablation technique called irreversible electroporation (IRE) in combination with anti-PD-1 antibody, an immune checkpoint inhibitor, could cure about 40% of treated mice bearing an aggressive PDAC tumor in the pancreas. In order to find ways to further increase the rate of complete response, we analyzed tumor microenvironment and found that a type of immune...